|
Jul 30
|
Why Drugmaker Teva Pharmaceutical Narrowed Full-Year Guidance After Beating Q2 Earnings
|
|
Jul 30
|
Teva CEO on Tariffs, Generic Drugs Market, MFN Pricing
|
|
Jul 30
|
Teva Pharma Boosts Outlook For Key Innovative Drugs Austedo, Ajovy, Uzedy
|
|
Jul 30
|
Alvotech Gears Up to Report Q2 Earnings: Here's What to Expect
|
|
Jul 30
|
Compared to Estimates, Teva Pharmaceutical Industries (TEVA) Q2 Earnings: A Look at Key Metrics
|
|
Jul 30
|
UZEDY® Accelerates: 2025 Revenue Outlook Raised to $190–$200M (from ~$160M); Olanzapine LAI on Track for Submission in 2025
|
|
Jul 30
|
Teva's Innovative Portfolio Fuels 10th Consecutive Quarter of Growth in Q2 2025; Increases 2025 Revenue Outlook for Key Innovative Products and EPS, and Reaffirms All Other Components
|
|
Jul 29
|
Countdown to Teva Pharmaceutical Industries (TEVA) Q2 Earnings: Wall Street Forecasts for Key Metrics
|
|
Jul 28
|
This is the Most Dangerous Week for Investors in 20 Years
|
|
Jul 25
|
S&P 500 Gains and Losses Today: Deckers Stock Jumps as Global Footprint Grows; Intel Shares Sink
|
|
Jul 24
|
Deckers Brands Reports First Quarter Fiscal Year 2026 Financial Results
|
|
Jul 21
|
EdgeOne Medical Announces Appointment of Michael Denzer as VP, Client Relations to Further Elevate Product Innovation and Client Partnerships
|
|
Jul 21
|
Should J&J Stock Be in Your Portfolio After Q2 Beat & Guidance Raise?
|
|
Jul 18
|
Trump Aims Tariff Double Whammy at Industries, Nations by Aug. 1
|
|
Jul 16
|
JNJ Begins Drug Sector Q2 Earnings With a Beat & Guidance Raise
|
|
Jul 14
|
Deckers Brands Announces Conference Call to Review First Quarter Fiscal 2026 Earnings Results
|
|
Jul 11
|
TEVA Stock Up More than 20% in Three Months: Buy, Sell or Hold the Stock?
|
|
Jun 17
|
Teva Partners With Fosun to Develop TEV-56278 Immuno-Cancer Therapy
|
|
Jun 17
|
Generic Drugmakers Resist Trump’s Calls for More U.S. Manufacturing
|
|
Jun 17
|
Teva, Fosun Pharma partner to develop TEV-56278
|